Harvard College

Ucb Biopharma Sprl

Gökhan S Hotamisligil

Ralph Adams

Kerry Louise Tyson

Carl Brendan Doyle

Karine Jeannine Madeleine Hervé

Mehmet F Burak

Adrian Richard Moore

Feyza Engin

Shauna Mhairi Wales

Scott B Widenmaier

Elisabeth Helen Roberts

Karen Inouye

Kosei Eguchi

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as 'aP2') for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders

Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and/or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

Method of treating idiopathic pulmonary fibrosis and kidney fibrosis

Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders

Growing community of inventors

Wellesley, MA, United States of America

Gökhan S Hotamisligil